Elicera Therapeutics AB (8E8)
Market Closed
14 Aug, 20:00
XFRA XMUN Primary XFRA €
0. 24
-0
-0.4202%
€
- Market Cap
- P/E Ratio
- Div Yield
1,150 Volume
0 Eps
€ 0.24
Previous Close Want to track 8E8 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
8E8 closed Friday lower at €0.24, a decrease of -0.4202% from Thursday's close, completing a monthly increase of 12.5891% or €0.03. Over the past 12 months, 8E8 stock lost -47.6243%.
8E8 is not paying dividends to its shareholders.
The last earnings report, released on May 16, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XMUN (EUR).
8E8 Chart
Elicera Therapeutics AB (8E8) FAQ
What is the stock price today?
The current price is €0.24.
On which exchange is it traded?
Elicera Therapeutics AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 8E8.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Elicera Therapeutics AB ever had a stock split?
No, there has never been a stock split.
Elicera Therapeutics AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jamal El-Mosleh M.Sc. CEO | XFRA Exchange | - ISIN |
| SE Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Elicera Therapeutics AB, a public company based in Gothenburg, Sweden, is at the forefront of immuno-oncology, focusing on the development of cell and gene therapies aimed at treating cancer through immune-based treatments. Since its inception in 2014, Elicera Therapeutics has dedicated itself to advancing its research and clinical trials to combat various cancer types, leveraging its scientific expertise and collaboration, notably with the esteemed Josep Carreras Leukemia Research Institute. This partnership seeks to utilize the innovative iTANK platform, enhancing the therapeutic potential of the company's pioneering treatments.
Products and Services
- ELC-100: Currently in Phase I/II clinical trial, ELC-100 is a groundbreaking treatment aimed at neuroendocrine tumors. This indicates significant progress in addressing a malignancy characterized by its unique set of challenges, underlining Elicera Therapeutics’ commitment to diversifying therapeutic options for cancer patients.
- ELC-201: This candidate focuses on the treatment of various injectable solid tumors, expanding the spectrum of cancers that Elicera Therapeutics targets. Its development reflects the company's broader mission to tackle the complexity of cancer through innovative immuno-oncology strategies.
- ELC-301: A CAR T-cell therapy formulated for the treatment of Non-Hodgkin's B-cell lymphoma, ELC-301 exemplifies Elicera Therapeutics’ expertise in cell and gene therapy. By leveraging the body's own immune system, ELC-301 represents a promising avenue for patients battling this type of lymphoma.
- ELC-401: Another CAR T-cell therapy, ELC-401, is designed to address solid tumors, an area that has traditionally posed significant challenges in cancer treatment. Through this therapy, Elicera Therapeutics aims to broaden the impact of immuno-oncology, offering hope to patients with solid tumors.
Contact Information
Address: World Trade Center Göteborg, Gothenburg, Sweden, 412 51
Phone: 46 7 03 31 90 51
Website: https://www.elicera.com
